评估重返工作岗位干预措施对健康和经济的影响:一项模型研究。

IF 4.9 2区 医学 Q1 ECONOMICS Value in Health Pub Date : 2024-11-21 DOI:10.1016/j.jval.2024.10.3850
Niccolò Morgante, Gudrun M W Bjørnelv, Lene Aasdahl, Cindy Nguyen, Natalia Kunst, Marius S Fimland, Emily A Burger
{"title":"评估重返工作岗位干预措施对健康和经济的影响:一项模型研究。","authors":"Niccolò Morgante, Gudrun M W Bjørnelv, Lene Aasdahl, Cindy Nguyen, Natalia Kunst, Marius S Fimland, Emily A Burger","doi":"10.1016/j.jval.2024.10.3850","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The rate of sickness absence in Norway is at its highest point since 2009 and policy makers need tools to make informed decisions on high-value interventions to address sick leave. Using trial-linked registry data, multi-state modelling, and decision-analytic modelling, we assessed the cost-effectiveness of two return-to-work (RTW) interventions for individuals with musculoskeletal and psychological disorders in Norway.</p><p><strong>Methods: </strong>Using data from 166 individuals in a randomized trial, we developed a decision-analytic model to compare two multi-domain RTW interventions: O-ACT (outpatient acceptance and commitment therapy) and I-MORE (inpatient multimodal occupational rehabilitation). The probabilistic model was informed using trial-based input parameters, including transition probabilities, healthcare costs, production loss, and health-related quality of life to project long-term costs and quality-adjusted life years (QALY) over a 25-year time horizon for each intervention.</p><p><strong>Results: </strong>Modelled outcomes were consistent with the trial outcomes, showing that I-MORE led participants to RTW more quickly. However, assuming a healthcare perspective and a cost-effectiveness threshold of $50,000 per QALY, I-MORE was not considered cost-effective in 98% of our simulations (probabilistic ICER: $356,447 per QALY gained) compared to O-ACT. In contrast, when accounting for production loss, I-MORE not only became cost-effective but was projected to be more beneficial and less costly compared to O-ACT.</p><p><strong>Conclusion: </strong>Under current Norwegian benchmarks for cost-effectiveness, I-MORE would not be considered cost-effective unless production loss was included. Our findings emphasize the key role of a broader societal perspective in economic evaluations, which although is being considered, is currently not recommended in Norwegian guidelines.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating the health and economic impacts of return-to-work interventions: a modelling study.\",\"authors\":\"Niccolò Morgante, Gudrun M W Bjørnelv, Lene Aasdahl, Cindy Nguyen, Natalia Kunst, Marius S Fimland, Emily A Burger\",\"doi\":\"10.1016/j.jval.2024.10.3850\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The rate of sickness absence in Norway is at its highest point since 2009 and policy makers need tools to make informed decisions on high-value interventions to address sick leave. Using trial-linked registry data, multi-state modelling, and decision-analytic modelling, we assessed the cost-effectiveness of two return-to-work (RTW) interventions for individuals with musculoskeletal and psychological disorders in Norway.</p><p><strong>Methods: </strong>Using data from 166 individuals in a randomized trial, we developed a decision-analytic model to compare two multi-domain RTW interventions: O-ACT (outpatient acceptance and commitment therapy) and I-MORE (inpatient multimodal occupational rehabilitation). The probabilistic model was informed using trial-based input parameters, including transition probabilities, healthcare costs, production loss, and health-related quality of life to project long-term costs and quality-adjusted life years (QALY) over a 25-year time horizon for each intervention.</p><p><strong>Results: </strong>Modelled outcomes were consistent with the trial outcomes, showing that I-MORE led participants to RTW more quickly. However, assuming a healthcare perspective and a cost-effectiveness threshold of $50,000 per QALY, I-MORE was not considered cost-effective in 98% of our simulations (probabilistic ICER: $356,447 per QALY gained) compared to O-ACT. In contrast, when accounting for production loss, I-MORE not only became cost-effective but was projected to be more beneficial and less costly compared to O-ACT.</p><p><strong>Conclusion: </strong>Under current Norwegian benchmarks for cost-effectiveness, I-MORE would not be considered cost-effective unless production loss was included. Our findings emphasize the key role of a broader societal perspective in economic evaluations, which although is being considered, is currently not recommended in Norwegian guidelines.</p>\",\"PeriodicalId\":23508,\"journal\":{\"name\":\"Value in Health\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Value in Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jval.2024.10.3850\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ECONOMICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jval.2024.10.3850","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

摘要

目标:挪威的病假率达到了 2009 年以来的最高点,政策制定者需要一些工具来就解决病假问题的高价值干预措施做出明智的决策。我们利用与试验相关的登记数据、多州建模和决策分析建模,评估了针对挪威肌肉骨骼和心理疾病患者的两种重返工作岗位(RTW)干预措施的成本效益:利用随机试验中 166 人的数据,我们建立了一个决策分析模型,对两种多领域重返工作干预措施进行比较:O-ACT(门诊接受与承诺疗法)和I-MORE(住院多模式职业康复)。该概率模型采用了基于试验的输入参数,包括过渡概率、医疗成本、生产损失和与健康相关的生活质量,以预测每种干预措施在25年时间跨度内的长期成本和质量调整生命年(QALY):模拟结果与试验结果一致,表明 I-MORE 使参与者更快地恢复正常工作。然而,假设从医疗保健角度出发,成本效益阈值为每 QALY 50,000 美元,在我们 98% 的模拟中,I-MORE 与 O-ACT 相比不具有成本效益(概率 ICER:每 QALY 收益 356,447 美元)。相比之下,如果考虑到生产损失,I-MORE不仅具有成本效益,而且与O-ACT相比,预计效益更高,成本更低:结论:根据挪威现行的成本效益基准,除非将产量损失计算在内,否则I-MORE不会被视为具有成本效益。我们的研究结果强调了更广泛的社会视角在经济评估中的关键作用,尽管挪威的指导方针正在考虑这种视角,但目前并不推荐。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluating the health and economic impacts of return-to-work interventions: a modelling study.

Objectives: The rate of sickness absence in Norway is at its highest point since 2009 and policy makers need tools to make informed decisions on high-value interventions to address sick leave. Using trial-linked registry data, multi-state modelling, and decision-analytic modelling, we assessed the cost-effectiveness of two return-to-work (RTW) interventions for individuals with musculoskeletal and psychological disorders in Norway.

Methods: Using data from 166 individuals in a randomized trial, we developed a decision-analytic model to compare two multi-domain RTW interventions: O-ACT (outpatient acceptance and commitment therapy) and I-MORE (inpatient multimodal occupational rehabilitation). The probabilistic model was informed using trial-based input parameters, including transition probabilities, healthcare costs, production loss, and health-related quality of life to project long-term costs and quality-adjusted life years (QALY) over a 25-year time horizon for each intervention.

Results: Modelled outcomes were consistent with the trial outcomes, showing that I-MORE led participants to RTW more quickly. However, assuming a healthcare perspective and a cost-effectiveness threshold of $50,000 per QALY, I-MORE was not considered cost-effective in 98% of our simulations (probabilistic ICER: $356,447 per QALY gained) compared to O-ACT. In contrast, when accounting for production loss, I-MORE not only became cost-effective but was projected to be more beneficial and less costly compared to O-ACT.

Conclusion: Under current Norwegian benchmarks for cost-effectiveness, I-MORE would not be considered cost-effective unless production loss was included. Our findings emphasize the key role of a broader societal perspective in economic evaluations, which although is being considered, is currently not recommended in Norwegian guidelines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Value in Health
Value in Health 医学-卫生保健
CiteScore
6.90
自引率
6.70%
发文量
3064
审稿时长
3-8 weeks
期刊介绍: Value in Health contains original research articles for pharmacoeconomics, health economics, and outcomes research (clinical, economic, and patient-reported outcomes/preference-based research), as well as conceptual and health policy articles that provide valuable information for health care decision-makers as well as the research community. As the official journal of ISPOR, Value in Health provides a forum for researchers, as well as health care decision-makers to translate outcomes research into health care decisions.
期刊最新文献
Value Attribution for Combination Treatments: Two Potential Solutions for an Insoluble Problem. Evaluating the health and economic impacts of return-to-work interventions: a modelling study. Exploring social preferences for health and wellbeing across the digital divide. A qualitative investigation based on tasks taken from an online discrete choice experiment. Quantifying low-value care in Germany: An observational study using statutory health insurance data from 2018 to 2021. Indirect Costs of Alzheimer's Disease: Unpaid Caregiver Burden and Patient Productivity Loss.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1